Occupancy of platelet receptors for platelet-activating factor in patients with septicemia.
Open Access
- 1 May 1989
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 83 (5) , 1733-1740
- https://doi.org/10.1172/jci114074
Abstract
The possible involvement of platelet-activating factor (PAF) in the pathogenesis of endotoxemia, was investigated by using a binding assay to patients' platelets, complemented with the extraction and chemical characterization of PAF obtained from patients' platelets. Platelets from 12 human volunteers had 281 +/- 63 freely accessible high affinity binding sites (PAF-receptors) per platelet; whereas this number was of 49 +/- 37 PAF-receptors per platelet, n = 14 samples, P less than 0.01, in a group of 13 patients with positive blood culture. A group of patients with respiratory or cardiovascular disturbances and negative blood culture had 253 +/- 74, accessible receptors per platelet (n = 19 samples from 16 patients, P less than 0.01 as compared to septic patients, which was not significantly different when compared to control individuals). Patients with sepsis possessed significant amounts of PAF associated to their platelets, whereas this mediator could not be isolated from platelets of patients with respiratory or cardiovascular disturbances and negative blood culture, nor from platelets of control individuals. PAF was also assayed in whole blood samples and found at high concentrations in sepsis patients. These data indicate that occupancy of PAF receptors in combination with high amounts of platelet-associated PAF, is a common finding in patients with sepsis.Keywords
This publication has 48 references indexed in Scilit:
- Preformed PAF‐acether and lyso PAF‐acether are bound to blood lipoproteinsFEBS Letters, 1988
- A Controlled Clinical Trial of High-Dose Methylprednisolone in the Treatment of Severe Sepsis and Septic ShockNew England Journal of Medicine, 1987
- Increased levels of platelet‐activating factor in blood from patients with cirrhosis of the liverEuropean Journal of Clinical Investigation, 1987
- Association of Platelet-Activating Factor with Primary Acquired Cold UrticariaNew England Journal of Medicine, 1985
- Specific binding sites for platelet activating factor in human lung tissuesBiochemical and Biophysical Research Communications, 1985
- Inhibition of binding of the platelet-activating factor AGEPC to platelets by the AGEPC analog rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate (CV-3988)Biochemical and Biophysical Research Communications, 1985
- Presence of platelet-activating factor in blood from humans and experimental animals. Its absence in anephric individualsBiochemical and Biophysical Research Communications, 1984
- Antihypertensive activity of an alkyl ether analog of phosphatidylcholineBiochemical and Biophysical Research Communications, 1979
- The role of platelet-activating factor in platelet aggregationNature, 1979
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959